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Coinfection with Schistosoma mansoni reactivates viremia in
rhesus macaques with chronic simian-human immunodeficiency
virus clade C infection
Abstract
We tested the hypothesis that helminth parasite coinfection would intensify viremia and accelerate
disease progression in monkeys chronically infected with an R5 simian-human immunodeficiency virus
(SHIV) encoding a human immunodeficiency virus type 1 (HIV-1) clade C envelope. Fifteen rhesus
monkeys with stable SHIV-1157ip infection were enrolled into a prospective, randomized trial. These
seropositive animals had undetectable viral RNA and no signs of immunodeficiency. Seven animals
served as virus-only controls; eight animals were exposed to Schistosoma mansoni cercariae. From
week 5 after parasite exposure onward, coinfected animals shed eggs in their feces, developed
eosinophilia, and had significantly higher mRNA expression of the T-helper type 2 cytokine
interleukin-4 (P = 0.001) than animals without schistosomiasis. Compared to virus-only controls, viral
replication was significantly increased in coinfected monkeys (P = 0.012), and the percentage of their
CD4(+) CD29(+) memory cells decreased over time (P = 0.05). Thus, S. mansoni coinfection
significantly increased viral replication and induced T-cell subset alterations in monkeys with chronic
SHIV clade C infection.
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We tested the hypothesis that helminth parasite coinfection would intensify viremia and accelerate disease
progression in monkeys chronically infected with an R5 simian-human immunodeficiency virus (SHIV) encoding a
human immunodeficiency virus type 1 (HIV-1) clade C envelope. Fifteen rhesus monkeys with stable SHIV-1157ip
infection were enrolled into a prospective, randomized trial. These seropositive animals had undetectable viral RNA
and no signs of immunodeficiency. Seven animals served as virus-only controls; eight animals were exposed to
Schistosoma mansoni cercariae. From week 5 after parasite exposure onward, coinfected animals shed eggs in their
feces, developed eosinophilia, and had significantly higher mRNA expression of the T-helper type 2 cytokine
interleukin-4 (P  0.001) than animals without schistosomiasis. Compared to virus-only controls, viral replication
was significantly increased in coinfected monkeys (P  0.012), and the percentage of their CD4 CD29 memory
cells decreased over time (P  0.05). Thus, S. mansoni coinfection significantly increased viral replication and
induced T-cell subset alterations in monkeys with chronic SHIV clade C infection.
Since human immunodeficiency virus type 1 (HIV-1) is
widespread in most developing countries where parasitic infec-
tions are highly prevalent, the likelihood of coinfection is high,
and the interaction between these infections in the same host
is an important clinical consideration. The host’s ability to
mount an immune response to a new pathogen and the nature
of that response are greatly determined by the preexisting state
of the immune system. For example, it has been suggested that
the T helper type 2 (Th2)-skewed immune profile and anergy
that are associated with helminth parasite infections jeopardize
the host’s ability to generate protective immunity to other
infectious agents, including HIV-1 (6–10, 28, 29). Data to sup-
port this hypothesis come from studies of mice exposed to
vaccinia virus expressing HIV envelope antigens. Compared to
control animals, mice with schistosomiasis displayed a shift
towards a Th2 response, with down-regulation of Th1 cytokine
production and impaired cytotoxic T-lymphocyte activity to the
coinfecting virus (1). Similarly, humans infected with Schisto-
soma mansoni have an impaired antigen-specific Th1-type re-
sponse following immunization with tetanus toxoid (35).
Alteration of immune responses can also be caused by other
helminthic infections. For example, signal transduction follow-
ing in vitro stimulation of lymphocytes obtained from individ-
uals with chronic helminth parasite infection is downregulated,
as are proliferative responses to purified protein derivative and
delayed-type hypersensitivity reactions to Mycobacterium bovis
bacillus Calmette-Guerin (BCG) (11). Elimination or reduc-
tion of intestinal worm infections in individuals subsequently
vaccinated with BCG resulted in a significant improvement in
Th1-type purified protein derivative-specific immune re-
sponses (17). Recently, these in vitro observations were sup-
ported by the in vivo observation that schistosome infections
are a risk factor for progression to active tuberculosis in Ugan-
dan HIV-1 patients (14).
Despite the observations that parasitic worms shift immune
responses to coinfecting agents, the influence of schistosomiasis
or other helminth infections on the course of HIV-1 infection and
disease progression remains controversial. Some studies support
the hypothesis that parasitic infections associated with Th2-type
immune responses increase the host’s susceptibility to HIV-1 and
promote viral replication in coinfected hosts. For example, pe-
ripheral blood mononuclear cells (PBMCs) from persons infected
with helminths were shown to be more susceptible to HIV-1
infection in vitro than cells from uninfected persons (19, 37). In
addition, expression of the HIV coreceptors CXCR4 and CCR5
on CD4 lymphocytes was significantly higher in patients with
active schistosomiasis than in individuals who had been treated
for their schistosomiasis (36). Furthermore, plasma HIV-1 viral
loads were reduced significantly in coinfected patients following
successful treatment with antihelminthics (40). However, a drop
in circulating viral load in HIV-1-positive individuals following
treatment for schistosomiasis or other helminths was not ob-
served in a number of other studies (12, 13, 18, 25, 32). A recent
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comparison of early versus delayed (by 3 months) treatment for
schistosomiasis also found no immediate drop in circulating viral
concentration (24). However, the progressive increase in viral
load and CD4 T-cell loss was halted in the persons who received
early treatment compared to those who were treated later, con-
firming the benefit of schistosome clearance in persons with
HIV-1 (24).
Due to the variability of results in the human studies, the
uncertainty of infectious agent doses and duration of viral or
parasite infections in patients, and the limited immune re-
sponse data for these individuals, we have begun evaluating
schistosome-primate immunodeficiency virus coinfections in
rhesus macaques. Our initial work demonstrated that schisto-
some-infected macaques intravenously inoculated with simian-
human immunodeficiency virus (SHIV) clade C had signifi-
cantly higher acute viral RNA loads compared to parasite-free
animals challenged with the same dose of virus (15). In addi-
tion, animals with previous SHIV infections that were subse-
quently infected with schistosomes demonstrated an increased
viral load coincident with the acute phase of the schistosome
infection. However, these findings were limited by the small
number of animals studied and the use of each animal as its
own control. We have now extended these findings with a
prospective, randomized study that involved another, larger
group of animals with preexisting chronic, stable R5 SHIV
clade C infection but no previous exposure to schistosomes.
We also examined alterations in the immune response profiles
of coinfected and control animals to assess effects of schisto-
somiasis on SHIV disease progression.
MATERIALS AND METHODS
Animals. Rhesus monkeys (Macaca mulatta) of Indian origin were housed at
the Yerkes National Primate Research Center (YNPRC) at Emory University, a
facility fully accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. Protocols were approved and animals
were maintained in accordance with the guidelines of the Institution Animal
Care and Use Committees for Emory University and the Dana-Farber Cancer
Institute. All procedures employed were consistent with the Guide for Care and
Use of Laboratory Animals (23a). All animals were negative for SIV, simian
T-lymphotropic virus type 1, and simian retrovirus type D and free of helminth
infection prior to our study. Fifteen monkeys that had been infected with R5
SHIV clade C strain SHIV-1157ip 1.5 to 4 years earlier were enrolled into a
controlled, prospective trial. These seropositive animals had no signs of immu-
nodeficiency and had undetectable plasma viral RNA for at least 3 months; they
were 1.5 to 4 years of age (mean age, 2.5 years) at enrollment. Seven animals
served as controls; the other eight were percutaneously exposed to S. mansoni
cercariae. Animals were monitored prospectively for clinical parameters (weight,
physical exams, complete blood cell counts, liver and renal function tests, and
T-cell subsets), plasma viral RNA, expression of cytokines and chemokines,
expression of markers of immune activation and viral coreceptors, and specific
immune responses. Virus-only controls were monitored for 14 weeks, and coin-
fected animals were monitored for 20 weeks.
R5 SHIV clade C. SHIV-1157ip (39) consists of an SHIV-vpu backbone (27)
and encodes most of gp120 and all of the extracellular and transmembrane
regions of gp41 of the primary HIV clade C strain HIV1157i, which had been
isolated from a 6-month-old Zambian infant with in utero infection (43). The
initial SHIV construct, the infectious molecular clone SHIV-1157i, was adapted
by serial blood transfer through a cohort of five rhesus monkeys that consisted of
two infants, two neonates, and one juvenile. Three of these five monkeys had
progressed to AIDS, and two remained long-term nonprogressors. AIDS, as
defined by an absolute peripheral CD4 T-cell count of200 cells/l, developed
at approximately week 140 in the first animal; the other two progressed to AIDS
within approximately 300 weeks postinoculation. SHIV-1157ip has also caused
thrombocytopenia. The passaged virus, SHIV-1157ip, was isolated from PBMCs
of the fifth animal. The monkeys enrolled in the current study were infected with
a stock of SHIV1157ip that had been grown in rhesus monkey PBMCs (39).
Schistosoma mansoni inoculations. Animals were anesthetized with ketamine
and percutaneously exposed to 500 cercariae of a Puerto Rican strain of S.
mansoni. An area on the abdomen was shaved, and cercariae were placed on the
skin within a metal ring for 30 min to allow penetration. To monitor infection,
fresh stool was obtained and processed by formalin-ethyl acetate sedimentation
and concentration. Schistosome eggs were counted by microscopic examination.
Quantitation of plasma viral RNA load and simian cytokine mRNAs. Periph-
eral blood samples were obtained by venipuncture and collected into Vacutainer
cell preparation tubes containing sodium citrate (Becton Dickinson, Rutherford,
NJ). Plasma and mononuclear cells were separated by centrifugation according
to the manufacturer’s instructions. Plasma samples from infected monkeys were
stored at 80°C until viral RNA loads were assessed by real-time reverse tran-
scription-PCR (20). For preparation of mRNA, cells were washed once in RPMI
1640 (Invitrogen, Carlsbad, CA), lysed with RLT lysis buffer (QIAGEN, Valen-
cia, CA) containing 1% -mercaptoethanol (Sigma Chemical Company, St.
Louis, MO), and stored at 80°C. Cytokine mRNA levels were assessed by a
quantitative real-time reverse transcription-PCR assay based on TaqMan chem-
istry (23). Variability in cytokine expression resulting from any disparities in cell
numbers or RNA isolation efficiency was corrected by normalization against
mRNA levels of the housekeeping gene coding for pyruvate dehydrogenase
(PDH).
Enumeration of T-cell subsets and phenotypic characterization of lympho-
cytes by flow cytometry. Complete blood cell counts, differential, and enumera-
tion of T-cell subsets in whole blood of animals collected at different time points
were measured at YNPRC as described previously (2). Immunophenotyping of
PBMCs from the animals was performed at Dana-Farber Cancer Institute by
three-color flow cytometry analysis, using a fluorescence-activated cell sorter
(Becton Dickinson Immunocytometry Systems) and CELLQuest software (Bec-
ton Dickinson). For surface staining, the cells were resuspended in staining
buffer (phosphate-buffered saline [PBS] containing 15% fetal calf serum and
0.1% NaN3) and incubated for 30 min at 4C with combinations of the following
antihuman monoclonal antibodies: CD3 conjugated with fluorescein isothiocya-
nate (FITC), CD4 conjugated with peridinin-chlorophyll-protein complex
(PerCP), CD8-FITC, and CD29 conjugated with phycoerythrin, which cross-
react with rhesus monkey surface markers (Becton Dickinson and BD Bio-
sciences PharMingen). The cell samples were then washed with PBS and fixed for
30 min at 4C with 1 ml of PBS containing 4% paraformaldehyde (Sigma-
Aldrich). A total of 106 events were acquired. Appropriate isotype-matched
control FITC-, phycoerythrin-, or PerCP-conjugated mouse or rat immunoglob-
ulin G1/immunoglobulin G2a monoclonal antibodies were used to obtain the
settings (Becton Dickinson and BD Biosciences PharMingen).
Cellular immune responses. PBMCs were tested for virus-specific responses
against overlapping SIV of macaques 239 (SIVmac239) Gag peptide pools
(AIDS Research & Reference Reagent Program, NIAID, NIH). To perform
short-term enzyme-linked immunospot (ELISPOT) assays, cells were cultured at
a final concentration of 2  106 cells per ml in RPMI 1640 that had been
supplemented with 15% heat-inactivated FCS, 2 mM L-glutamine, 200 g/ml
streptomycin, 200 U/ml penicillin, and 5  105 -mercaptoethanol. Cells were
cultured in 96-well ELISPOT plates (100 l per well) for 16 to 18 h without
stimulation, with overlapping SIVmac239 Gag peptide pools at a final concen-
tration of 2 g/ml of each peptide, or with 25 ng/ml phytohemagglutinin and 1
g/ml ionomycin at 37°C in a 5% CO2 environment. Gamma interferon (IFN-)
ELISPOT assays were developed using the BD human IFN- ELISPOT kit
(Becton Dickinson and BD Biosciences PharMingen) according to the manufac-
turer’s instructions. For long-term ELISPOT assays, cells were cultured at a final
concentration of 5  106 cells per ml in 24-well plates for 10 days with overlap-
ping SIVmac239 Gag peptide pools at a final concentration of 2 g/ml of each
peptide. Interleukin-2 (IL-2) was added to the cultures every 3 days at a final
concentration of 10 U/ml. On day 10, cells were washed, counted, and restimu-
lated as described above for short-term ELISPOT assays.
Statistical analyses. Generalized estimation equations were used to model the
data collected over time and to compare parasite-negative and S. mansoni-
coinfected groups (41, 42). The Wilcoxon rank-sum test was used to compare
single-time-point data (26). All P values reported are for two-sided significance
tests. P values of 0.05 were considered significant, and P values between 0.05
and 0.1 were considered marginally significant.
RESULTS
Parasite coinfection of rhesus monkeys with chronic SHIV-
1157ip infection. To test whether S. mansoni challenge would
reactivate viral replication in monkeys with chronic stable
1752 AYASH-RASHKOVSKY ET AL. INFECT. IMMUN.
SHIV clade C infection, a cohort of 15 rhesus monkeys that
had been inoculated with SHIV-1157ip 1.5 to 4 years earlier
was enrolled into a prospective, randomized trial. These chron-
ically infected animals were seropositive but had no signs of
immunodeficiency and had shown no detectable plasma viral
RNA for at least 3 months prior to enrollment. Seven of these
SHIV-1157ip-infected animals served as the parasite-negative
control group. The other eight animals were percutaneously
exposed to 500 S. mansoni cercariae. Beginning at week 5 after
coinfection, parasite-challenged animals demonstrated signs
indicative of S. mansoni infection: parasite eggs in stools (Fig.
1A) and eosinophilia (Fig. 1B). S. mansoni infection was es-
tablished in all parasite-challenged monkeys.
Cytokine profiles and cellular activation markers. The lev-
els of mRNA expression of the Th2 cytokines IL-4 (Fig. 2A)
and IL-6 (Fig. 2B) were higher in the ex vivo PBMCs of
virus-infected monkeys with concurrent schistosomiasis than in
virus-only controls (P 0.001, Fig. 2A, and P	 0.074, Fig. 2B,
respectively) at week 9 after S. mansoni infection. No differ-
ences were observed in mRNA expression levels for IL-2,
IFN-, tumor necrosis factor alpha, and RANTES (data not
shown).
Influence of S. mansoni infection on plasma viral RNA loads.
To test whether schistosome coinfection would reactivate clin-
ically latent SHIV-1157ip replication, we prospectively moni-
tored both groups of animals for viral RNA loads at weekly or
semiweekly intervals. Whereas viral RNA loads in the control
group remained at very low levels, coinfected animals devel-
oped viral RNA spikes of 
104 copies/ml (Fig. 3). Compared
to control animals, this increase of viral replication in coin-
fected monkeys was significant (P 	 0.012), albeit transient,
and coincided with the acute stage of S. mansoni infection. We
tested for associations between egg counts and viral loads but
found no significant correlations.
Influence of S. mansoni infection on T-cell subset profiles
and antiviral immune parameters. To test whether monkeys
with schistosomiasis would demonstrate accelerated develop-
ment of immunodeficiency compared to those free of parasites,
FIG. 1. Infection of rhesus macaques with S. mansoni. Eight ani-
mals were percutaneously exposed to 500 cercariae. (A) Egg counts in
stool samples collected from the S. mansoni-inoculated animals. Data
represent the running average of three consecutive values. SEM, stan-
dard error of the mean. (B) Percentage of eosinophils in SHIV-1157ip-
infected rhesus monkeys with and without concurrent schistosomiasis.
In coinfected animals, the percentage of eosinophils rose as a function
of time of infection.
FIG. 2. Ex vivo PBMC cytokine mRNA levels in S. mansoni-in-
fected or control rhesus macaques. Shown is IL-4 (A) and IL-6
(B) mRNA expression relative to the expression of the housekeeping
gene coding for PDH in PBMCs from control or schistosome-infected
animals at 9 weeks after exposure to cercariae. Data represent column
means  standard deviations. Groups were compared by Wilcoxon’s
rank-sum test.
FIG. 3. Acute schistosome infection reactivates latent viral infec-
tion. Plasma viral RNA loads in SHIV-1157ip-infected animals with
loads that had been low to undetectable (50 copies/ml) were elevated
concurrent with acute S. mansoni infection. Generalized estimation
equations were used to compare viral loads between the two groups
over time (P 	 0.012).
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we prospectively monitored the SHIV-1157ip-positive animals
with or without parasites for absolute numbers of CD4 T
cells, CD4/CD8 ratios, and the percentages of CD4
CD29 memory T cells.
No significant changes were observed in absolute CD4
T-cell numbers, CD4/CD8 ratios, or the percentages of
CD4 CD29 memory T cells in the controls during the 14-
week period of observation. In the coinfected group, the ab-
solute numbers of CD4 T cells and the CD4/CD8 ratios
similarly remained unchanged. However, the percentage of
CD4 CD29 memory T cells in coinfected monkeys de-
creased from 5 weeks of infection onward (P	 0.05, Fig. 4). By
18 weeks after inoculation with schistosomes, the mean per-
centage in coinfected animals fell to 10%, the lower limit for
normal CD4 CD29 memory T cells (4, 16, 22, 31).
We also evaluated whether coinfected animals responded dif-
ferently to viral antigens compared to parasite-free, SHIV-in-
fected monkeys. PBMCs were tested for specific responses to
overlapping SIVmac239 Gag peptide pools by IFN- ELISPOT
assays. All animals from both groups produced IFN- in response
to the peptides, and there were no statistically significant differ-
ences in the numbers of IFN--secreting T cells between animals
infected with SHIV only and coinfected monkeys in either short-
term (1,198  1,656 [standard deviation] spot-forming units
[SFU] per 106 cells versus 1,667  1,956 SFU per 106 cells; P 	
0.627) or long-term assays (1,138 1,520 SFU per 106 cells versus
2,737  2,622 SFU per 106 cells; P 	 0.181). Finally, we tested
whether the levels of anti-SHIV antibodies changed in parasite-
positive versus parasite-free monkeys; no statistically significant
differences were seen over the course of the experiment as mea-
sured by anti-SIV Gag enzyme-linked immunosorbent assay.
DISCUSSION
Coinfection with S. mansoni significantly increased viral repli-
cation and induced alterations in the T-cell subsets in monkeys
with chronic, clinically stable SHIV clade C infection. From week
5 after S. mansoni exposure onward, coinfected animals shed
parasite eggs in the stool, developed eosinophilia, and expressed
mRNA of the Th2 cytokine IL-4 at significantly higher levels than
animals without schistosomiasis. Compared to virus-only controls,
viral replication was significantly increased in the coinfected mon-
keys. Although the spikes in plasma viral RNA were tran-
sient, they coincided with the acute stage of schistosomiasis,
when Th2 responses are strongest. In contrast to virus-only
controls, the percentage of CD4 CD29 memory T cells
decreased in the coinfected group starting from week 5 after
coinfection until the end of follow-up.
The results of the present study support our previous obser-
vation that parasite infection upregulates R5 SHIV clade C
replication (15). In the earlier pilot study, no parasite-free, virus-
only control group was enrolled in parallel to the coinfected
group. Data from the present prospective, controlled trial support
the hypothesis that S. mansoni infection and the ensuing estab-
lishment of the Th2-skewed cytokine milieu reactivate latent virus
and may promote immunologic deterioration.
Previous studies have demonstrated that a decrease in the
percentage of CD4 CD29 memory T cells is an early sign of
immune dysfunction and a prognostic parameter for the de-
velopment of subsequent immunodeficiency (4, 16, 22, 31). In
our primate studies (4, 5, 21; unpublished data), depletion of
CD4 CD29 memory T cells preceded the loss of absolute
numbers of CD4 T cells by several months to years. Within
the time of follow-up of the current two groups of monkeys, we
did not observe significant changes in either absolute CD4
T-cell counts or CD4/CD8 ratios.
The transient character of the viral reactivation could pos-
sibly be ascribed to the transient nature of schistosome infec-
tions in rhesus macaques. Although these animals are permis-
sive hosts for schistosomiasis in that they allow establishment
of patent infections, most monkeys clear the parasites follow-
ing the acute phase of infection without treatment intervention
(30, 38). In humans, where schistosome infections are more
persistent, the elevation of plasma viremia may similarly be
prolonged. From these data, we cannot predict whether per-
sons with chronic schistosomiasis would similarly experience
increased viral replication or if only persons who have acute
schistosomiasis would be affected. However, the observation
that coinfected persons who received early treatment for their
schistosomiasis demonstrated significantly lower increases in
viral loads and CD4 T-cell declines compared to persons
whose treatment was delayed for as little as 3 months argues
strongly that any schistosome infection in HIV-positive indi-
viduals promotes immunologic deterioration (24).
Nonhuman primate studies, while imperfect models of hu-
man infection for schistosomes or immunodeficiency viruses,
may provide important insights into disease progression and
extend the ability to address questions that are difficult to
evaluate in human populations. For example, our previous
rhesus coinfection study (15) showing that acute immunodefi-
ciency virus replication is elevated in schistosome-infected
monkeys and our present study showing reactivation of viral
replication during the acute phase of schistosomiasis would be
impossible to assess in humans. Another area in which the
primate coinfection model may prove useful is the assessment
of HIV-1 vaccine efficacy in the presence of helminths. The
effects of schistosomiasis and other helminthic infections on
the modulation of immune responses are well established (3,
10, 33, 34), and alterations in response to vaccination as a
consequence of schistosome infection have been demonstrated
(35). It is likely that human field trials testing the efficacy of
FIG. 4. Memory T-cell analysis in SHIV-1157ip-infected monkeys.
The percentage of CD4 CD29 memory T cells was stable in animals
infected with SHIV-1157ip alone but decreased over time in coinfected
macaques. Generalized estimation equations were used to model the
data collected over time (P 	 0.05). The dotted line represents the
lower limit of normal for the percentage of CD4 CD29 memory T
cells. SEM, standard error of the mean.
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HIV candidate vaccines will take place in Africa and Asia,
areas with a high incidence of HIV infections. However, po-
tentially effective vaccines may show suboptimal results if such
clinical trials are confounded by the immune activation and/or
cytokine profiles that may be shifted by helminth infections
that predominate in the developing world. Well-planned stud-
ies utilizing the nonhuman primate model for parasite-immu-
nodeficiency virus coinfection as described here, in which
pathogens, timing, route, and dose can be controlled, may yield
critical adjunctive information for the successful implementa-
tion of HIV-1 and other vaccination programs.
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